Endospan, Ltd. appears in FDA records as the applicant behind the NEXUS Aortic Arch Stent Graft System, filed under product code SDZ and generic name "Endovascular System for Treatment of Ascending Aorta and Aortic Arch Lesions." The original application, P250033, was filed on August 22, 2025, and approved on April 2, 2026. A later supplement, P250033/S004, was received June 23, 2026, and approved September 21, 2026. The supplied collection contains two linked PMA records, both with approved decisions, and the record sample lists the same two entries. [1][2][5]

The approved device and its stated indication

The NEXUS Aortic Arch Stent Graft System is recorded as a class 3 device under product code SDZ, reviewed in the Cardiovascular advisory committee assignment. The approval statement for P250033 describes the indication as endovascular treatment of chronic dissections involving the aortic arch in patients at high risk for open surgical repair who have appropriate anatomy. The SSED identifies the device generic name as Endovascular Graft and notes breakthrough device status granted March 27, 2020. [2][3]

The SSED lists assessment areas including device integrity, device migration, loss of aortic or aortic branch patency, reinterventions, and technical success. The supplied excerpt does not report outcome values for these areas, so no performance figures are stated here. [3]

Filing history and supplement scope

The original PMA was filed August 22, 2025, amended January 6, 2026, and approved April 2, 2026, with a Federal Register notice date of April 7, 2026. The approval letter is addressed to Endospan Ltd care of a regulatory consultant in Wilmington, Delaware; that correspondence address is a filing contact point, not a company headquarters. [2][5]

Supplement S004 was received June 23, 2026, and approved September 21, 2026, on the Normal 180 Day Track. Its stated scope is a labeling change covering indications, instructions, shelf life, or tradename, and the approval statement specifies a three-year shelf life for the system. The FDA PMA database entry notes that a device with supplements may have a changed description or indication, directing readers to the supplements for current information. [1][8]

Company identity and brand context

The SSED gives the applicant's address as 4 Maskit St., Herzliya, Israel. The FDA structured records list Alta, Wyoming addresses associated with registration numbers, which are filing data rather than a verified corporate headquarters. [1][3]

Artivion product pages describe the NEXUS system as a purpose-built Zone 0 arch branch and ascending device, citing a pre-curved delivery system and a two-stage procedure; these are the publisher's characterizations. An Endospan page carries a news item titled "Advancing Innovation Together: Welcoming Endospan to Artivion, Inc." The public documents do not establish the legal ownership structure, so the relationship between Endospan and Artivion is not confirmed here. [4][6][10]

What the linked FDA records do not show

The collection counts reflect only the supplied filings as of the snapshot date: two linked PMA records, both approved, and no recall records in the sample. These are filing counts, not measures of total portfolio, sales, or safety performance. The public documents contain no verified company website, customer list, certification, or commercial availability statement, and none is asserted. [1][2]